Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Comprehensive Genomic Profiling Opens Up More Treatment Possibilities For Your Patients FoundationOne® and FoundationOne® Heme are pan-cancer comprehensive genomic profiles that identify all classes of genomic alterations (base substitutions, copy number alterations, insertions/deletions, and gene rearrangements) in a patient’s cancer and match them with relevant targeted therapies and clinical trials based on the latest scientific and clinical data. This unique genomic profile based on an individual patient’s molecular drivers enables more personalized healthcare solutions to optimize treatment outcomes. Comprehensive and Trusted Conserve Tissue and Save Time • Identifies all classes of genomic alterations with >99% specificity, with validation published in a peer-reviewed journal.1 • Identifies 3X more targeted therapy options than traditional standard of care tests and hotspot panels.1 • Requires only a small amount of tissue including routine biopsy samples and FNA specimens. • Can be performed on low purity samples. Informative, Relevant and Actionable Results • All clinically relevant alterations identified are matched to targeted therapies and clinical trials based on current scientific evidence and published clinical data. • Report is powered by 20+ bioinformaticians and genomic scientists combined with state-of-the-art algorithms to report the most clinically relevant information for a patient. More Than Just a Test FoundationACCESS support services help patients and providers with: • Reimbursement and financial assistance for FoundationOne testing. • Comprehensive case management when reimbursement issues create obstacles to off label or investigational therapies. • Clinical trials navigation for patients. 1 Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013 Nov;31(11):1023-31. PubMed PMID: 24142 For Solid Tumors For Hematologic Malignancies And Sarcomas Sequences the entire coding region of 315 cancer-related genes plus select introns from 28 genes Sequences the entire coding region of 405 cancer-related genes and the RNA of 265 genes commonly rearranged in cancer Comprehensive Genomic Profiling Rearrangements Base substitutions Insertions and deletions Copy number alterations